Velavigo

VelaVigo is a biotechnology company specializing in the discovery and development of advanced biologics, including antibody-drug conjugates (ADCs), multi-specific antibodies, and T-cell engagers, with a strong focus on innovative drug discovery platforms. Founded in October 2021 by Dr. Jing Li with an initial $50 million investment, the company operates global R&D headquarters in Shanghai and maintains clinical and business operations in Boston to facilitate international dealmaking and licensing. VelaVigo generates revenue primarily through out-licensing its proprietary biologics and entering exclusive option agreements with pharmaceutical partners, as evidenced by multiple high-profile licensing deals. The company is recognized for its efficient discovery engine and translational capabilities, and it has quickly established itself as a leader in the antibody/ADC biotech space. Its rapid growth and cross-continental presence highlight its ambition to advance novel therapies and forge global partnerships in the biopharma industry.

Recent Posts by Velavigo

1-1 of 1